Wave Life Sciences annual operating margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Wave Life Sciences's operating margin was −504.09% for fiscal 2025.
View full Wave Life Sciences company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −504.09% | −402.15 pp |
| 2024 | 2024-12-31 | −101.94% | −41.93 pp |
| 2023 | 2023-12-31 | −60.01% | +4399.29 pp |
| 2022 | 2022-12-31 | −4,459.30% | −4149.24 pp |
| 2021 | 2021-12-31 | −310.07% | +453.88 pp |
| 2020 | 2020-12-31 | −763.94% | +539.42 pp |
| 2019 | 2019-12-31 | −1,303.37% | −196.64 pp |
| 2018 | 2018-12-31 | −1,106.72% | +1523.41 pp |
| 2017 | 2017-12-31 | −2,630.13% | +2472.43 pp |
| 2016 | 2016-12-31 | −5,102.56% | +7593.49 pp |
| 2015 | 2015-12-31 | −12,696.05% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −3,248.33% | −3070.61 pp |
| Q1 2026 | 2026-03-31 | −81.83% | +193.00 pp |
| Q2 2025 | 2025-06-30 | −606.49% | −542.20 pp |
| Q1 2025 | 2025-03-31 | −542.82% | −551.85 pp |
| Q2 2024 | 2024-06-30 | −177.72% | −71.54 pp |
| Q1 2024 | 2024-03-31 | −274.83% | −40.59 pp |
| Q4 2023 | 2023-12-31 | −64.30% | +3451.68 pp |
| Q3 2023 | 2023-09-30 | 9.03% | +13657.80 pp |
| Q2 2023 | 2023-06-30 | −106.18% | +11137.55 pp |
| Q1 2023 | 2023-03-31 | −234.24% | +1942.56 pp |
| Q4 2022 | 2022-12-31 | −3,515.98% | −3495.10 pp |
| Q3 2022 | 2022-09-30 | −13,648.77% | −12214.05 pp |
| Q2 2022 | 2022-06-30 | −11,243.73% | −10922.59 pp |
| Q1 2022 | 2022-03-31 | −2,176.80% | −1179.26 pp |
| Q3 2021 | 2021-09-30 | −20.89% | +1256.15 pp |
| Q2 2021 | 2021-06-30 | −1,434.73% | −233.26 pp |
| Q4 2020 | 2020-12-31 | −321.15% | +2201.06 pp |
| Q3 2020 | 2020-09-30 | −997.54% | +852.21 pp |
| Q2 2020 | 2020-06-30 | −1,277.04% | −679.02 pp |
| Q1 2020 | 2020-03-31 | −1,201.47% | +384.39 pp |
| Q4 2019 | 2019-12-31 | −2,522.21% | −1170.19 pp |
| Q3 2019 | 2019-09-30 | −1,849.74% | −998.82 pp |
| Q2 2019 | 2019-06-30 | −598.02% | +151.58 pp |
| Q1 2019 | 2019-03-31 | −1,585.86% | +929.97 pp |
| Q4 2018 | 2018-12-31 | −1,352.02% | +1485.69 pp |
| Q3 2018 | 2018-09-30 | −850.92% | +1153.11 pp |
| Q2 2018 | 2018-06-30 | −749.60% | +1499.53 pp |
| Q1 2018 | 2018-03-31 | −2,515.82% | +2760.16 pp |
| Q4 2017 | 2017-12-31 | −2,837.70% | +1558.47 pp |
| Q3 2017 | 2017-09-30 | −2,004.03% | +786.86 pp |
| Q2 2017 | 2017-06-30 | −2,249.13% | +1711.18 pp |
| Q1 2017 | 2017-03-31 | −5,275.98% | −2395.82 pp |
| Q3 2016 | 2016-09-30 | −4,396.17% | +8930.75 pp |
| Q2 2016 | 2016-06-30 | −2,790.89% | — |
| Q3 2015 | 2015-09-30 | −3,960.32% | — |
| Q2 2015 | 2015-06-30 | −2,880.16% | — |
| Q1 2015 | 2015-03-31 | −13,326.92% | — |
Over the last five reported fiscal years, Wave Life Sciences's operating margin increased from −763.94% to −504.09%, a change of +259.85 percentage points. The latest reported quarter, Q2 2026, shows −3,248.33%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Wave Life Sciences filings at SEC.gov ↗